| Drug Name |
Dextroamphetamine |
| Drug ID |
BADD_D00636 |
| Description |
Dextroamphetamine is the dextrorotary enantiomer of amphetamine[A2505]. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label]. |
| Indications and Usage |
Dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).[Label] |
| Marketing Status |
approved; illicit |
| ATC Code |
N06BA02 |
| DrugBank ID |
DB01576
|
| KEGG ID |
D03740
|
| MeSH ID |
D003913
|
| PubChem ID |
5826
|
| TTD Drug ID |
D0T3LF
|
| NDC Product Code |
68968-0215; 72162-2043; 68968-0220; 68968-0210; 68968-0205; 27808-085 |
| UNII |
TZ47U051FI
|
| Synonyms |
Dextroamphetamine | Dexamphetamine | Dexamfetamine | dextro-Amphetamine | dextro Amphetamine | d-Amphetamine | d Amphetamine | Dexedrine | DextroStat | Oxydess | Curban | Dextroamphetamine Sulfate | Sulfate, Dextroamphetamine | Dextro-Amphetamine Sulfate | Dextro Amphetamine Sulfate | d-Amphetamine Sulfate | d Amphetamine Sulfate |
